Literature DB >> 24834943

Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations.

Arman Jahangiri1, Jeffrey Wagner, Sung Won Han, Corinna C Zygourakis, Seunggu J Han, Mai T Tran, Liane M Miller, Maxwell W Tom, Sandeep Kunwar, Lewis S Blevins, Manish K Aghi.   

Abstract

UNLABELLED: OBJECT.: While transsphenoidal surgery is associated with low morbidity, the degree to which morbidity increases after reoperation remains unclear. The authors determined the morbidity associated with repeat versus initial transsphenoidal surgery after 1015 consecutive operations.
METHODS: The authors conducted a 5-year retrospective review of the first 916 patients undergoing transsphenoidal surgery at their institution after a pituitary center of expertise was established, and they analyzed morbidities.
RESULTS: The authors analyzed 907 initial and 108 repeat transsphenoidal surgeries performed in 916 patients (9 initial surgeries performed outside the authors' center were excluded). The most common diagnoses were endocrine inactive (30%) or active (36%) adenomas, Rathke's cleft cysts (10%), and craniopharyngioma (3%). Morbidity of initial surgery versus reoperation included diabetes insipidus ([DI] 16% vs 26%; p = 0.03), postoperative hyponatremia (20% vs 16%; p = 0.3), new postoperative hypopituitarism (5% vs 8%; p = 0.3), CSF leak requiring repair (1% vs 4%; p = 0.04), meningitis (0.4% vs 3%; p = 0.02), and length of stay ([LOS] 2.8 vs 4.5 days; p = 0.006). Of intraoperative parameters and postoperative morbidities, 1) some (use of lumbar drain and new postoperative hypopituitarism) did not increase with second or subsequent reoperations (p = 0.3-0.9); 2) some (DI and meningitis) increased upon second surgery (p = 0.02-0.04) but did not continue to increase for subsequent reoperations (p = 0.3-0.9); 3) some (LOS) increased upon second surgery and increased again for subsequent reoperations (p < 0.001); and 4) some (postoperative hyponatremia and CSF leak requiring repair) did not increase upon second surgery (p = 0.3) but went on to increase upon subsequent reoperations (p = 0.001-0.02). Multivariate analysis revealed that operation number, but not sex, age, pathology, radiation therapy, or lesion size, increased the risk of CSF leak, meningitis, and increased LOS. Separate analysis of initial versus repeat transsphenoidal surgery on the 2 most common benign pituitary lesions, pituitary adenomas and Rathke's cleft cysts, revealed that the increased incidence of DI and CSF leak requiring repair seen when all pathologies were combined remained significant when analyzing only pituitary adenomas and Rathke's cleft cysts (DI, 13% vs 35% [p = 0.001]; and CSF leak, 0.3% vs 9% [p = 0.0009]).
CONCLUSIONS: Repeat transsphenoidal surgery was associated with somewhat more frequent postoperative DI, meningitis, CSF leak requiring repair, and greater LOS than the low morbidity characterizing initial transsphenoidal surgery. These results provide a framework for neurosurgeons in discussing reoperation for pituitary disease with their patients.

Entities:  

Keywords:  DI = diabetes insipidus; LOS = length of stay; morbidity; oncology; pituitary surgery; reoperation; transsphenoidal surgery

Mesh:

Year:  2014        PMID: 24834943     DOI: 10.3171/2014.3.JNS131532

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

Review 1.  The surgical treatment of acromegaly.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Hypophysitis: a single-center case series.

Authors:  Brandon S Imber; Han S Lee; Sandeep Kunwar; Lewis S Blevins; Manish K Aghi
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

3.  Operative Strategies to Minimize Complications Following Resection of Pituitary Macroadenomas.

Authors:  Jayesh P Thawani; Ashwin G Ramayya; Jared M Pisapia; Kalil G Abdullah; John Y-K Lee; M Sean Grady
Journal:  J Neurol Surg B Skull Base       Date:  2016-12-07

4.  Outcome of Endoscopic Transsphenoidal Surgery for Recurrent or Residual Pituitary Adenomas and Comparison to Non-Recurrent or Residual Cohort by Propensity Score Analysis.

Authors:  Xuan Gong; Yang Zhuo; Huichun Yuan; Kui Yang; Chuntao Li; Songshan Feng; Mingyu Zhang; Zhenyan Li; Hongshu Zhou; Zhixiong Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

5.  A practical method for prevention of readmission for symptomatic hyponatremia following transsphenoidal surgery.

Authors:  William T Burke; David J Cote; Sherry I Iuliano; Hasan A Zaidi; Edward R Laws
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 6.  ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.

Authors:  Priscilla K Brastianos; Sandro Santagata
Journal:  Eur J Endocrinol       Date:  2015-11-12       Impact factor: 6.664

7.  Comparative study of complications after primary and revision transsphenoidal endoscopic surgeries.

Authors:  Leandro Custódio do Amaral; Baltazar Leão Reis; Antônio Ribeiro-Oliveira; Thamires Marx da Silva Santos; Alexandre Varella Giannetti
Journal:  Neurosurg Rev       Date:  2020-08-11       Impact factor: 3.042

Review 8.  Surgery for acromegaly: Indications and goals.

Authors:  David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-04       Impact factor: 6.055

9.  Low complication rate of sellar reconstruction by artificial dura mater during endoscopic endonasal transsphenoidal surgery.

Authors:  Yuanliang Ye; Fuyu Wang; Tao Zhou; Yi Luo
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

10.  Pituitary Hormonal Status after Endoscopic Endonasal Transphenoidal Removal of Nonfunctioning Pituitary Adenoma: 5 years' Experience in a Single Center.

Authors:  Pungjai Keandoungchun; Wuttipong Tirakotai; Ampai Phinthusophon; Yodkhwan Wattanasen; Patcharapim Masayaanon; Sudasawan Takathaweephon
Journal:  Asian J Neurosurg       Date:  2021-03-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.